fig4

Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Figure 4. Changes in cfRNA levels during therapy when cfDNA is unmeasurable. cfRNA and cfDNA were measured at initiation of treatment and at various times during chemotherapy using PCR amplification of Β-actin. Treatment efficacy of chemotherapy regimens was determined by CT scans. PCR: Polymerase chain reaction.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/